Press-release for stocks related to positive listed in the nyse exchange

Prices are updated after-hours

tags : Positive exchanges : Nyse

save search

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| 0.75% | O: 0.75% H: 0.0% C: 0.0%
rinvoq positive cell results study

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Published: 2024-04-11 (Crawled : 11:00) - prnewswire.com
MS | News | $90.66 0.44% 0.07% 8.1M

Finance

| -1.87% | O: -0.74% H: 0.09% C: -5.32%
LPCN | $5.33 -2.02% -2.06% 11K

Health Technology

| -9.83% | O: 6.78% H: 13.49% C: 1.75%
obesity positive results

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -4.27% | O: 0.73% H: 2.49% C: 0.11%
abrysvo disease positive risk for rsv results study

Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
Published: 2024-04-08 (Crawled : 22:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -4.51% | O: -0.3% H: 0.0% C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| -3.41% | O: 0.05% H: 0.02% C: -2.62%
MOR | News | $17.96 -0.5% -0.5% 180K

Health Technology

| -0.55% | O: 0.06% H: 0.22% C: 0.0%
KNSA | $16.93 0.3% 0.3% 380K

Health Technology

| -4.52% | O: 0.23% H: 1.58% C: 0.06%
IMAB | $1.81 0.56% 0.55% 340K

Health Technology

| -0.55% | O: -0.55% H: 1.39% C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K

Health Technology

| -8.29% | O: 0.0% H: 0.39% C: -0.66%
positive growth market

Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -3.12% | O: 0.17% H: 0.28% C: -0.01%
fabhalta first chmp positive novartis

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 3.24% | O: 0.0% H: 0.68% C: 0.63%
pneumococcal vaccine merck positive

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M

n/a

| -11.43% | O: 7.14% H: 5.53% C: -4.67%
cyb003 fda positive meeting program design

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -8.49% | O: 0.21% H: 0.17% C: 0.14%
tak-079 positive topline potential results study

Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -10.4% | O: -0.21% H: 0.11% C: -1.06%
adcetris positive trial

New Research Confirms Positive Impact of OneMain's BUILD Credit Education
Published: 2024-03-07 (Crawled : 23:00) - prnewswire.com
OMF | $48.7 1.67% 0.0% 780K

Finance

| -2.7% | O: 0.66% H: 0.65% C: -1.0%
positive research education impact

Alibaba Releases Report on Cross-Border Trade's Positive Impact on the U.S. Economy
Published: 2024-03-06 (Crawled : 11:00) - prnewswire.com
BABA | $69.07 0.28% -0.07% 13M

Retail Trade

| -3.41% | O: 2.96% H: 0.7% C: -0.66%
report positive impact

Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
Published: 2024-02-29 (Crawled : 16:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -5.99% | O: 0.11% H: 0.44% C: -1.88%
abrysvo positive rsv

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -9.66% | O: 0.28% H: 0.0% C: 0.0%
LEGN | $46.14 -2.08% -2.12% 1.2M

Health Technology

| -23.66% | O: 2.07% H: 5.02% C: 4.92%
carvykti chmp biotech positive treatment therapy

Gray Finishes 2023 In A Strong Position and Issues Positive Outlook for 2024
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
GTN | $5.92 2.25% 0.0% 860K

Consumer Services

| -29.43% | O: -8.43% H: 1.65% C: -15.66%
positive

ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
Published: 2024-02-12 (Crawled : 21:00) - globenewswire.com
RMD | $178.85 0.7% 0.0% 1.2M

Health Technology

| -4.76% | O: -1.57% H: 1.1% C: -0.27%
positive therapy

REVALESIO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 RESCUE STUDY OF RNS60 IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN LATE-BREAKING ORAL PRESENTATION AT ISC 2024
Published: 2024-02-07 (Crawled : 23:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 6.49% | O: 0.76% H: 4.31% C: 2.11%
rns60 stroke presentation positive topline study

Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
Published: 2024-02-07 (Crawled : 22:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -8.28% | O: -0.63% H: 0.0% C: 0.0%
PTGX | $25.61 1.55% 1.52% 450K

Health Technology

| -0.75% | O: -0.04% H: 4.09% C: 2.8%
jnj-2113 psoriasis positive results study

J&J Touts Positive Phase III Results for Antibody in Autoimmune Disorders
Published: 2024-02-06 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology